The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Xarelto LawsuitsThe dates for the first bellwether trials in the pending Xarelto litigation are planned to begin in August of 2016, according to minute entries from a June 22nd meeting.

Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana has ordered the selection of fifty cases from the Xarelto Multidistrict Litigation (MDL) to be included for potential bellwether trials.

Judge Fallon also mentioned that the first trial is planned to begin on August 1st, 2016.

About Xarelto & Pending Lawsuits

Xarelto is a popular anticoagulant drug – also known as a blood thinner – which is prescribed for the prevention of blood clots, stroke and related medical conditions.

After its FDA approval in 2011, Xarelto quickly became the leading blood thinner in its class with more than 11 million prescriptions in the US to date.

However, the drug has come under fire recently after studies linked the blood thinner to serious side effects including uncontrollable bleeding.

Due to these recent findings, people throughout the country are filing lawsuits against the manufacturers and distributors of the drug claiming that the companies were negligent.

Among other accusations, Plaintiffs in these cases allege that Bayer AG and Johnson & Johnson did not provide sufficient safety testing and failed to report dangerous side effects of Xarelto which the companies had been aware of.

Xarelto Lawyers Assisting Plaintiffs

“The results of these initial bellwether trials will be very helpful for our clients and all other parties involved in the Xarelto litigation,” commented Stephen A. Sheller, Esq. in response to the recent developments.

Sheller is a sponsor of the online resource which provides information about Xarelto lawsuits, as well as access to legal representation for those who wish to file a complaint.

Contact Information

Marc Goldich, Esq.

Comments are closed.